2013-08-15 07:33:03 -
Seneffe - Belgium, August 15, 2013, Eckert & Ziegler BEBIG (Euronext: EZBG;
Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today its financial results
for the first half of 2013.
The report including the milestones and a selection of consolidated key figures
of the first half of 2013 can be downloaded at:
www.bebig.eu > Investor Relations > Financial Reports
Eckert & Ziegler BEBIG
...Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group, active in the medical device
sector of the healthcare industry.
Its core business is the treatment of cancer by brachytherapy, a special form of
radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and
is headquartered in Belgium. It has a production facility in Germany and
subsidiaries throughout Europe, as well as in India and in
Brazil. Eckert &
Ziegler BEBIG has also established a worldwide network of distributors and
agents to support its product line.
The company's products and equipment are intended for use by oncologists,
radiologists, urologists and medical physicists.
Eckert & Ziegler BEBIG employs about 150 people. It has been listed on the
Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR;
Bloomberg: EZBG: BB).
Eckert & Ziegler BEBIG s.a.
Tel: +32 (0) 64 520 808
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE